Physician profile
Gary S Midla
NPI 1124000237
$896.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $325 · 2021: $32.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $164.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $143.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $91.85 | 2019-2021 | |
| Amarin Pharma, INC. | $79.77 | 2019-2020 | |
| Astellas Pharma US INC | $66.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $54.37 | 2019-2020 | |
| Novo Nordisk INC | $50.36 | 2019-2020 | |
| Amgen INC. | $48.21 | 2019 | |
| Lilly USA, LLC | $47.99 | 2019-2020 | |
| Abbvie INC. | $34.61 | 2020-2021 | |
| Pfizer INC. | $23.66 | 2019 | |
| Merck Sharp & Dohme LLC | $23.54 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $19.53 | 2019 | |
| Sanofi Pasteur INC. | $12.78 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.60 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11.40 | 2020 | |
| Currax Pharmaceuticals LLC | $11.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Midla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.